Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST: TX200-TR101 CAR-Treg in Living Donor Kidney Transplant Recipients
2024-512579-11-00Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Mar 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of TX200 in kidney allograft rejection, sponsored by Sangamo Therapeutics. Primary endpoint: Incidence and grade of TEAEs including SAEs within 28 days post TX200-TR101 infusion. Started Mar 2021; status: completed.
02
Drugs
TX200
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-512579-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512579-11-00.